Turn­ing Point looks to chal­lenge Pfiz­er, Roche with new ear­ly da­ta for lead lung can­cer drug

Turn­ing Point Ther­a­peu­tics shared a Phase I/II up­date for its lead drug can­di­date re­potrec­tinib, but in­vestors said they were ex­pect­ing slight­ly bet­ter.

In 71 to­tal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER